NCT06004570
Effects of a Combination of Polyphenol-rich Extracts on the Protection of Retinal Cells Against Blue Light in the Prevention of Ocular Diseases No drug interventions supportive_care Not Available completed NCT06408701
Modeling Ocular Developmental Diseases From 3D Cultures of Optic Vesicle Organoids Derived From hiPSCs of Patients With Ocular Malformations No drug interventions Not Available Not Available not_yet_recruiting NCT04190147
Eye and Growth in Adolescents Born Moderate-to-late Preterm No drug interventions Not Available Not Available completed NCT01458613
Biomarker for Maroteaux-Lamy Disease (BioMaroteaux) No drug interventions Not Available Not Available withdrawn NCT04068818
The Heidelberg Engineering ANTERION Imaging Agreement Study No drug interventions Not Available Not Available completed NCT02585063
Independent Prescribing Optometrists in Acute Ophthalmic Services No drug interventions Not Available Not Available completed NCT04937725
Reading Problems Associated With Central Nervous System (CNS) Pathologies. No drug interventions Not Available Not Available completed NCT01740466
Epidemiological Profile of Ophthalmological Care in the Public Service in Brazil No drug interventions Not Available Not Available completed NCT05339880
Relation Between Oculocardiac Reflex and Laryngospasm No drug interventions Not Available Not Available unknown_status NCT02539381
The Stroke Vision App: A Screening Tool for Visual Stroke No drug interventions screening Not Available unknown_status NCT04118738
International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy No drug interventions Not Available Not Available completed NCT03913130
Extension Study to Study PQ-110-001 (NCT03140969) treatment 1 / 2 terminated NCT06627179
Study to Evaluate Ultevursen in Subjects with Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene treatment 2 not_yet_recruiting NCT04855045
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. treatment 2 / 3 unknown_status NCT03872479
Single Ascending Dose Study in Participants With LCA10 treatment 1 / 2 active_not_recruiting NCT03396042
Natural History Study of CEP290-Related Retinal Degeneration No drug interventions Not Available Not Available completed NCT05176717
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) treatment 2 / 3 terminated NCT05158296
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) treatment 2 / 3 terminated NCT03780257
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene treatment 1 / 2 completed NCT03913143
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) treatment 2 / 3 active_not_recruiting NCT00001161
Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens No drug interventions Not Available Not Available completed